On Thursday, Shares of Citrix Systems, Inc. (NASDAQ:CTXS), gained 2.95% to $72.62.
Citrix Systems, declared plans to spin off its Go To family of products into a separate, publicly traded company. The transaction, which is intended to be a tax-free spinoff to Citrix shareholders, is predictable to be accomplished in the second half of 2016. Citrix’s declarement to pursue a separation follows a thorough review of planned alternatives for the GoTo family of products.
Citrix believes that this planned decision will allow Citrix and the company established by the spinoff to enhance their planned focus and respective competitive positions, while permitting Citrix to improve operational efficiency. Right Away following the separation, Citrix shareholders will own shares in two publicly traded companies:
- The company established as a result of the spinoff will be made up of GoToAssist, GoToMeeting, GoToMyPC, GoToTraining, GoToWebinar, Grasshopper and OpenVoice. This company will more effectively allocate resources in line with its own market opportunity, unique growth precedingities and go-to-market capabilities, in addition to adapt more quickly to SaaS market and customer dynamics; and,
- Citrix, which will focus on its planned solutions for secure and reliable delivery of applications and data. Please see related news release here.
For the trailing twelve months ended September 30, 2015, unaudited revenues were about $600 million for the products and services to be spun off.
Citrix Systems, Inc. provides virtualization, mobility administration, networking, and Software as a Service solutions worldwide. The company’s Enterprise and Service Provider division offers Xen Mobile Enterprise, a solution to manage mobile devices, apps, and data; Xen Desktop, a desktop virtualization system that gives customers the flexibility to deliver desktops and applications as cloud services; Citrix XenApp that allows Windows applications to be delivered as cloud services to Android and iOS mobile devices, Macs, PCs, and thin clients; and Citrix Workspace Suite, a business mobility solution that delivers the user experience for any app or desktop.
Shares of Nuance Communications Inc. (NASDAQ:NUAN), declined -0.15% to $20.20, during its last trading session.
Nuance Communications, declared the availability of Dragon Anywhere for Android, bringing the powerful professional productivity features of Dragon desktop speech recognition to mobile devices for the first time. Available for Android smart phones and tablets and powered by the cloud, Dragon Anywhere is the only mobile dictation solution that offers continuous dictation – no time or length limits – robust voice formatting and editing, and customization features that can be synchronized across devices.
Dragon Anywhere allows field workers, lawyers, social workers, public safety officers and other professionals to improvement productivity by using their voice to create and edit complete reports and documents, capture detailed notes, and more, while on the go or in the field. Dragon Anywhere’s continuous dictation capabilities run in the cloud, allowing documents to be created without a time or length limit on dictation. Once a document is complete, it can be shared easily by email, via cloud-sharing tools like Dropbox, saved to note-taking apps like Evernote or shared with virtually any app via the clipboard.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
Finally, Shares of Bristol-Myers Squibb Co (NYSE:BMY), ended its last trade with -0.97% loss, and closed at $66.96.
Bristol-Myers Squibb Company, declared new long-term data of Opdivo in treatment-naïve BRAF wild-type advanced melanoma from CheckMate -066. In the trial, Opdivo continued to demonstrate superior overall survival as compared to dacarbazine with 57.7% of patients alive at two years contrast to 26.7% of patients treated with dacarbazine. The safety profile of Opdivo was compriseent with preceding studies. The two-year survival and safety data from CheckMate -066 represent the longest follow-up from a randomized study of any PD-1 immune checkpoint inhibitor in the first-line setting of advanced melanoma. These data will be presented as a late-breaking presentation at the Society for Melanoma Research (SMR) 2015 International Congress in San Francisco, CA from November 18 to 21.
Bristol-Myers Squibb is also presenting updated data from various Phase 1 cohorts of Study 004 evaluating the Opdivo + Yervoy Regimen in patients with unresectable or metastatic melanoma, counting up to three-year overall survival. The Phase 1b Study 004 is a dose-finding study on which the proof of concept for Opdivo + Yervoy Regimen approval was based.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.